Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set / Edition 1

Hardcover (Print)
Buy New
Buy New from BN.com
$1,536.00
Used and New from Other Sellers
Used and New from Other Sellers
from $116.68
Usually ships in 1-2 business days
(Save 92%)
Other sellers (Hardcover)
  • All (3) from $116.68   
  • New (2) from $573.75   
  • Used (1) from $116.68   

Overview

The Wiley Handbook of Current and Emerging Drug Therapies supports the information needs of research managers and scientists working in drug discovery environments in academia, industry, and government. A carefully structured program of online updating and successive print editions will ensure that the Handbook reflects the latest information on new molecular entities, clinical trials, drug approvals, and post-approval studies of new drugs. A landmark reference to support drug discovery and evidence-based medicine, the Wiley Handbook of Current and Emerging Drug Therapies will provide researchers, clinicians, and other professionals with essential scientific information on established and emerging drug treatments for common medical indications.

Read More Show Less

What People Are Saying

From the Publisher
We find the "Wiley Handbook of Current and Emerging Drug Therapies" a very useful resource in our reference collection. It provides our users with a good overview of the drug development process. And, also looks at therapeutic area trends in research and development of the top 20 pharmaceutical companies. Our users appreciate having a single source for acquiring information for both the analysis of currently approved drugs and those drugs emerging for the different therapeutic areas. The thorough bibliographies at the end of each section are also very helpful. In addition, the separate "subject" and "drug and molecular name" indexes make the handbook very easy to use.

— Sondra Pfeiffer, Librarian, University of Alabama at Birmingham

Read More Show Less

Product Details

  • ISBN-13: 9780470040980
  • Publisher: Wiley
  • Publication date: 12/5/2006
  • Edition number: 1
  • Pages: 2664
  • Product dimensions: 6.91 (w) x 10.04 (h) x 7.48 (d)

Table of Contents

PART I: INTRODUCTION.

The Drug Discovery Process.

Clinical Trials, Overview.

Therapeutic Area Trends in R&D of the Top 20 PharmaceuticalCompanies.

PART II: ONCOLOGY.

Aggressive Non-Hodgkin's Lymphomas.

Bladder Cancer.

Breast Cancer.

Cervical Cancer.

Chronic Lymphocytic Leukemia (CLL).

Chronic Myelogenous Leukemia.

Colorectal Cancer.

Malignant Melanoma.

Multiple Myeloma.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 2.

PART II: ONCOLOGY.

Non-Small-Cell Lung Cancer.

Ovarian Cancer.

Pancreatic Cancer.

Prostate Cancer.

Small-Cell Lung Cancer.

PART III: IMMUNE SYSTEM.

Allergic Rhinitis.

Asthma.

Crohn's Disease.

Psoriasis.

Rheumatoid Arthritis.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 3.

PART IV. METABOLIC DISEASES.

Diabetic Retinopathy.

Dyslipidemia.

Metabolic Syndrome.

Obesity.

Osteoporosis.

Type 1 Diabetes.

Type 2 Diabetes.

PART V. INFECTIOUS DISEASES.

Acute Exacerbations of Chronic Bronchitis.

Community-Acquired Pneumonia.

Complicated Skin and Soft Tissue Infections.

Hepatitis C.

Methicillin-Resistant Staphylococcus Aureus.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 4.

PART VI. EMERGING TECHNOLOGIES AND BUSINESSOPPORTUNITIES.

Data and Information Integration in Pharmaceutical R&D.

Impact of Technological Advances on PharmaceuticalProductivity.

Advances in Medicinal Chemistry and Lead Optimization.

Bio-Defense Opportunities in the Biotechnology andPharmaceutical Industries.

Fear of Theranostics: Why an Industry Has Not ReallyEmerged.

Beyond Commodity Drugs: Strategic Diversification in theGenerics Industry.

PART VII: GLOBAL MARKETS AND NATIONAL POLICY.

The EU Clinical Trials Directive: Impact in Europe andBeyond.

The Indian Pharmaceutical Industry in Transition: Changes andOpportunities Ahead.

Spotlight on the Australian and New Zealand Pharmaceutical andBiotechnology Industries.

Overview of the World's Major OTC Markets.

Biotech Hubs-Key Growth Engines for Drug Development.

Pharmaceutical Marketplace in Central and Eastern Europe.

Valuation Models for European Biotech.

Taking Global Action: Integrating Social Responsibility intoCorporate Practices.

Global Branding Strategy: From the Blockbuster to the TargetedModel.

PART VIII: NEW OPPORTUNITIES IN DRUG DISCOVERY AND PIPELINEDEVELOPMENT.

Prospects for Genomics-Derived Drugs: New Approaches and Impacton Pharmaceutical Pipelines.

Prying Open the Pipeline: Drug Discovery and Development in thePostgenomics Era.

Glycomics: The Impact of Carbohydrates on Biological Functionand the Implications for Drug Discovery.

High-Content Screening for Drug Discovery and TargetValidation.

High-Throughput ADMET Screening: Improving the Efficiency ofDrug Discovery.

Emerging Concepts in GPCR Research and Their Implications forDrug Discovery.

Optimizing Knowledge Management in Pharmaceutical Companies.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Cumulative Subject Index, Volumes 1-4.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)